Fig. 3: DP2-antagonist mediated resolution of airway remodeling is dependent on endogenous PGD2 and ablated by dual therapy with a corticosteroid. | Nature Communications

Fig. 3: DP2-antagonist mediated resolution of airway remodeling is dependent on endogenous PGD2 and ablated by dual therapy with a corticosteroid.

From: Dual therapy with corticosteroid ablates the beneficial effect of DP2 antagonism in chronic experimental asthma

Fig. 3

A–E Mice with CEA were Inoculated with RV-1b and given vehicle, DP2 antagonist or DP1 antagonist or both DP2 and DP1 antagonist daily from day 99 and euthanized at 7 dpi. Quantification of (A) ASM, (B) collagen deposition, (C) Mucus score and (D) TGF-β1 expression. Lung (E) EGF and (F) PGD2 levels in homogenates. G–L Mice with chronic asthma were inoculated with RV-1b and treated with vehicle, DP2 antagonist, fluticasone, or both drugs daily from day 99 and euthanized at 7 dpi. Quantification of (G) ASM, (H) collagen deposition, (I) Mucus score and (J) TGF-β1 expression. Lung (K) EGF and (L) PGD2 levels in homogenates. Data are presented as box-and-whisker plots showing individual data points with the boxes representing quartiles and whiskers indicating the range and are representative of two independent experiments (n = 5–7 mice per group). Statistical significance between different groups was determined using one-way ANOVA with Dunnett’s multiple comparison test. * denotes p < 0.05, ** denotes p < 0.01 and *** denotes p < 0.001 compared to vehicle group. δ denotes p < 0.05 and δδ denotes p < 0.01 compared to DP2 antagonist treated group. Source data are provided as a Source Data file.

Back to article page